Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
50
TLSI Quote, Financials, Valuation and Earnings
Last price:
$6.72
Seasonality move
:
29.79%
Day range:
$6.41 - $6.87
52-week range:
$3.42 - $7.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.28x
P/B ratio:
--
Volume:
207.9K
Avg. volume:
126.7K
1-year change:
62.62%
Market cap:
$321.3M
Revenue:
$29.4M
EPS (TTM):
-$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$11.8M | -$0.17 | 55.01% | -67.11% | $11.36 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
ICUI
ICU Medical, Inc.
|
$511.5M | $1.43 | -13.68% | 316.67% | $180.83 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.50 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | 2.34% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$6.43 | $11.36 | $321.3M | -- | $0.00 | 0% | 5.28x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.3900 | $12.3077 | $177.7M | -- | $0.00 | 0% | 162.05x |
|
ICUI
ICU Medical, Inc.
|
$142.35 | $180.83 | $3.5B | -- | $0.00 | 0% | 1.51x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.50 | $34.9M | -- | $0.00 | 0% | 19.49x |
|
VTAK
Catheter Precision, Inc.
|
$2.38 | -- | $2.9M | 0.40x | $0.00 | 0% | 11.19x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.60 | $1.50 | $83.7M | 58.61x | $0.00 | 0% | 0.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
461.2% | -0.594 | 14.71% | 2.54x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ICUI
ICU Medical, Inc.
|
39.35% | 0.320 | 46.61% | 1.02x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$9.7M | -$9M | -936.41% | -- | -77.94% | -$3.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ICUI
ICU Medical, Inc.
|
$202.3M | $28.3M | -0.21% | -0.36% | 5.26% | $25M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
TriSalus Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns TLSI or CATX?
Perspective Therapeutics, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -12425.36%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TLSI or CATX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.36, signalling upside risk potential of 76.63%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TLSI or CATX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock TLSI or CATX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or CATX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.28x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.28x -- $11.6M -$10.8M CATXPerspective Therapeutics, Inc.162.05x -- $209K -$26M
-
Which has Higher Returns TLSI or ICUI?
ICU Medical, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -0.63%. TriSalus Life Sciences, Inc.'s return on equity of -- beat ICU Medical, Inc.'s return on equity of -0.36%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ICUIICU Medical, Inc.37.63% -$0.14 $3.5B -
What do Analysts Say About TLSI or ICUI?
TriSalus Life Sciences, Inc. has a consensus price target of $11.36, signalling upside risk potential of 76.63%. On the other hand ICU Medical, Inc. has an analysts' consensus of $180.83 which suggests that it could grow by 27.03%. Given that TriSalus Life Sciences, Inc. has higher upside potential than ICU Medical, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than ICU Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 ICUIICU Medical, Inc.3 1 0 -
Is TLSI or ICUI More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.719%.
-
Which is a Better Dividend Stock TLSI or ICUI?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or ICUI?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than ICU Medical, Inc. quarterly revenues of $537.7M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than ICU Medical, Inc.'s net income of -$3.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while ICU Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.28x versus 1.51x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.28x -- $11.6M -$10.8M ICUIICU Medical, Inc.1.51x -- $537.7M -$3.4M
-
Which has Higher Returns TLSI or VNRX?
VolitionRX Ltd. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -862.39%. TriSalus Life Sciences, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About TLSI or VNRX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.36, signalling upside risk potential of 76.63%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 779.04%. Given that VolitionRX Ltd. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe VolitionRX Ltd. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 VNRXVolitionRX Ltd.4 1 0 -
Is TLSI or VNRX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock TLSI or VNRX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or VNRX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.28x versus 19.49x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.28x -- $11.6M -$10.8M VNRXVolitionRX Ltd.19.49x -- $627.3K -$5.4M
-
Which has Higher Returns TLSI or VTAK?
Catheter Precision, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -1037.17%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About TLSI or VTAK?
TriSalus Life Sciences, Inc. has a consensus price target of $11.36, signalling upside risk potential of 76.63%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Catheter Precision, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is TLSI or VTAK More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock TLSI or VTAK?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or VTAK?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.28x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.28x -- $11.6M -$10.8M VTAKCatheter Precision, Inc.11.19x 0.40x $226K -$2.3M
-
Which has Higher Returns TLSI or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 3.93%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About TLSI or XTNT?
TriSalus Life Sciences, Inc. has a consensus price target of $11.36, signalling upside risk potential of 76.63%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 150.92%. Given that Xtant Medical Holdings, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is TLSI or XTNT More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock TLSI or XTNT?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or XTNT?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 58.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.28x versus 0.65x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.28x -- $11.6M -$10.8M XTNTXtant Medical Holdings, Inc.0.65x 58.61x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
